Zevra Therapeutics (ZVRA) Operating Expenses (2014 - 2026)

Zevra Therapeutics has reported Operating Expenses for 13 years, with the latest figure at $25.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 10.4% year-over-year to $25.2 million; the trailing twelve-month figure through Mar 2026 stood at $92.7 million (down 4.95% YoY), and the FY2025 full-year result was $90.4 million, down 6.81% from the prior year.
• Operating Expenses for Q1 2026 stood at $25.2 million, up from $23.0 million in the prior quarter.
• The five-year high for Operating Expenses was $27.2 million in Q3 2024, with the low at $5.8 million in Q1 2022.
• Historically, Operating Expenses has averaged $20.6 million across 5 years, with a median of $22.9 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 323.65% — and 2023, when it sank 46.12%.
• Zevra Therapeutics' Operating Expenses stood at $11.3 million in 2022, then surged by 130.07% to $26.1 million in 2023, then dropped by 6.14% to $24.5 million in 2024, then slipped by 6.14% to $23.0 million in 2025, then advanced by 9.58% to $25.2 million in 2026.
• The last three Operating Expenses figures came in at $25.2 million (Q1 2026), $23.0 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.